Heart disease remains a leading cause of disability and mortality,[@b1],[@b2] not in the least due to today's aging population with its inherently heightened risk of heart failure.[@b3]

Mitochondrial dysfunction and perturbations of cardiac energy metabolism are recognized as contributors in heart failure of humans and animal models.[@b4]--[@b7] Mitochondria are cellular high-energy compounds and a major source of reactive oxygen species (ROS), which modulate the activity of diverse redox-sensitive signaling pathways. Importantly, several mitochondrially localized antioxidant systems maintain the intracellular redox balance.[@b8] Of these, the thioredoxin system, consisting of thioredoxin and thioredoxin reductase (TXNRD), is capable of reducing various disulfides and participates in different cellular processes,such as proliferation or cell death, via redox-controlled signaling.[@b9] The incorporation of the trace element selenium as selenocystein at the C-terminal redox active site is required for the catalytic activity of TXNRDs.[@b10] In livestock, selenium deficiency may cause white muscle disease, a myodegenerative disease affecting skeletal and cardiac muscle. Consistently, in humans, selenium deficiency is associated with cardiomyopathies, such as Keshan disease.[@b11]

*Txnrd2* is essential for mouse embryogenesis; its ubiquitouse deletion is associated with malformation of the embryonic heart. Cardiomyocyte-specific ablation of *Txnrd2* resulted in perinatal death with clinical features of congestive heart failure precluding studies in adult mice.[@b12] Inducible deletion of *Txnrd2* revealed an increased vulnerability of the left ventricle to ischemia--reperfusion injury (eg, larger infarct size and excess loss of function), which was amenable to treatment with ROS scavengers.[@b13]

Thus, malfunction of *Txnrd2* not only severely affects the developing heart but also causes an increased sensitivity toward acute heart stress. Such situations, however, may be considered extreme in their high-energy demand. They do not reflect the importance of a continuously intact mitochondrial thioredoxin system in the heart. This issue, however, is of high importance with respect to identifying key factors that determine heart well-being or failure in an aging population.

We therefore investigated *Txnrd2* function in the aging heart and demonstrate that *Txnrd2* is crucial for maintaining mitochondrial integrity and normal heart function during aging.

Methods
=======

Transgenic Mice
---------------

Mice carrying *lox*P-flanked *Txnrd2* alleles (*Txnrd2*^*flfl*^) were mated to heterozygous *Txnrd2*^*+/−*^ mice carrying a cardiomyocyte-specific *MerCreMer* transgene.[@b14] Generation and genotyping of *lox*P-flanked, heterozygous, and heart-specific knockout (KO) *Txnrd2* mice were described previously.[@b12],[@b15]

Tamoxifen was administrated orally as described.[@b15] In short, tamoxifen citrate salt (10051; Chemische Fabrik Berg GmbH) and sucrose at a final concentration of 3.6 g/kg and 5%, respectively, were added to a pelleted soy-free, low-phytoestrogen diet (ssniff M-Z Phytoestrogenarm, Ssniff Spezialdiäten GmbH). Tamoxifencontaining chow was fed ad libitum for 5 weeks starting at week 6. Before and after this period, animals were fed the standard mouse diet. Mice were bred and kept at the animal facilities of the Helmholtz Zentrum München in Type II Macrolon cages with wood shavings (Altromin) as bedding at a temperature of 20°C to 24°C and a 12/12-hour light/dark cycle. Mice had free access to a standardized mouse diet (1314, Altromin) and drinking water. All animal experiments were performed in compliance with the German animal welfare law and have been approved by the institutional animal care and use committee and by the District Government of Upper Bavaria.

Echocardiography
----------------

Functional heart assays have been performed in the cardiovascular module of the German Mouse Clinic (<http://www.mouseclinic.de/>).[@b16] Left ventricular (LV) function was determined with transthoracic echocardiography by using high-frequency ultrasound biomicroscopy with a 30-MHz transducer and 30-Hz frame rate (Vevo 660; VisualSonics). Shaved and anesthetized mice (1% isoflurane; Baxter) were fixed in supine position on a heated platform with ECG electrodes attached to monitor heart rate. Body temperature was 36°C to 38°C, monitored via use of a rectal thermometer (Indus Instruments). LV parasternal short-axis views were imaged in M-mode at the papillary muscle level. Measurements from 3 cardiac cycles each of 2 recordings were averaged for LV end-diastolic internal diameter (LVEDD) and LV end-systolic internal diameter (LVESD) by using the leading-edge convention, as suggested by the American Society of Echocardiography.[@b17] Fractional shortening was calculated as FS (%)=\[(LVEDD−LVESD)/LVEDD)\]×100, ejection fraction as EF (%)={\[7/(2.4+LVEDD)\]×(LVEDD)3−\[7/(2.4+LVESD)\]×(LVESD)3}. The echocardiographer was blinded to genotype.

Noninvasive Determination of Blood Pressure
-------------------------------------------

Blood pressure was measured in conscious mice with a noninvasive tail-cuff method by using the MC4000 Blood Pressure Analysis Systems (Hatteras Instruments Inc). Mice were restrained on a prewarmed metal platform in metal boxes. The tails were looped through a tail-cuff and fixed in a notch containing an optical path with an LED light and a photosensor. The blood pulse wave in the tail artery was detected by light extinction and transformed into a pulse amplitude signal. Pulse detection, cuff inflation, and pressure evaluation were automated by the system software. After 5 initial inflation runs for habituation, 12 measurement runs were performed for each animal in 1 session. Runs with movement artifacts were excluded. After 1 day of training, in which the animals were habituated to the apparatus and protocol, the measurements were performed on 4 consecutive days between 8:30 and 11:30 [am]{.smallcaps}. For each animal, 20 to 48 measurements were pooled to obtain a mean over the 4 measurement days.

Quantitative Real-Time Polymerase Chain Reaction
------------------------------------------------

Total RNA was isolated from whole heart homogenates by using peqGOLD TriFast reagent (30-2010; peqLab) and cDNA was generated by using a Reverse Transcription System kit (A3500; Promega Corp) by following the manufacturers' protocols. Quantitative real-time (RT)-polymerase chain reaction (PCR) was performed by using the 7500 Real Time PCR system (Applied Biosystem, Foster City, USA) and the Power SYBR Green PCR Master Mix (4367659, Applied Biosystems). Hearts were collected from 3 mice per genotype and time point. mRNA was isolated and analyzed independently in triplicate. The PCR (50°C for 2 minutes, denaturation at 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minutes) was performed in triplicate and normalized to endogenous *Gapdh* mRNA levels for each reaction. Quantification was done by using the comparative method (2^−ΔΔCt^) of relative quantification.[@b18] PCR product specificity was controlled by melting curve analysis. For quantification of *Txnrd2* mRNA levels, intron-spanning primers were designed by using Primer Express Software v2.0 (Applied Biosystems), and sequences were as follows: *Act b* F 5′-TTC CGA TGC CCT GAG GC-3′, *Act b* R 5′-TCA ACG TCA CAC TTC ATG ATG ATG G-3′; *Gapdh* E5 5′-CAA TGT GTC CGT GGA TC-3′, *Gapdh* E6 5′-CCT TCA GTG GGC CCT CAG A-3′; *Txnrd2* E16 5′GCT GGG CCT GCA CTT CCT-3′, *Txnrd2* E17 5′-CTG TCT GCA TCA CCT GTG CAT-3′; *Anp* F 5′-GGC CTT TTG GCT TCC AGG-3′, *Anp* R 5′-CCT CCA GGT GGT CTA GCA GGT-3′; *p62* F 5′-GAC AGA GCA AAT GAA AAA GAT AGC C-3′, and *p62* R 5′-AAA TGT GTC CAG TCA TCG TCT CC-3′. All other primer sequences were as reported previously.[@b19]--[@b22]

Description of Mouse Genes Quantified by RT-PCR
-----------------------------------------------

The mouse genes were *Acadl*, acyl-CoA dehydrogenase, long chain (NM_007381); *Acadm*, acyl-CoA dehydrogenase, medium-chain (NM_007382); *Acot2*, mitochondrial acyl-CoA thioesterase 2 (NM_134188); *ANP*, natriuretic peptide precursor type A (NM_008725); *Bnip3,* BCL2/adenovirus E1B interacting protein 3 (NM_009760); *BNP*, natriuretic peptide precursor type B (NM_008726); *Cd36*, fatty acid translocase (NM_007643); *Etfdh*, electron transferring flavoprotein, dehydrogenase (NM_025794); *Glut1*,*Slc2a1* solute carrier family 2 (facilitated glucose transporter), member 1 (NM_011400); *Gpx1*, glutathione peroxidase 1(NM_008160); *Hif1a,* hypoxia inducible factor 1, α subunit (NM_010431); *Ldh*, lactate dehydrogenase (NM_010699); *Pdha1*, pyruvate dehydrogenase E1 α1 (NM008810); *Pdk4*, pyruvate dehydrogenase kinase, isoenzyme 4 (NM_013743); *Ppara*, peroxisome proliferator-activated receptor α (NM_011144); *Ppargc1a*, peroxisome proliferator-activated receptor, γ, coactivator (NM_008904); *p62*,*Mus musculus* sequestosome 1 (Sqstm1) (NC_000077.6); *Sod1*, superoxide dismutase 1 (NM_011434); *Sod2*, superoxide dismutase 2 (NM_013671); *Tfam*, transcription factor A, mitochondrial (NM_009360); *Ucp2*, uncoupling protein2 (NM_011671); *Ucp3*, uncoupling protein3 (NM_009464); and *Vegfa*, vascular endothelial growth factor A (NC_000083.5).

Quantification of Mitochondrial DNA
-----------------------------------

Total cellular DNA was extracted and purified from frozen hearts by using the DNeasy Tissue kit (69504, Qiagen, Hilden, Germany). Total DNA concentration was determined with a fluorometer. Equal amounts of DNA were assayed in triplicate by RT-PCR as described above by using the primers reported previously.[@b19] The average threshold cycle (Ct) number values of nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) were used to calculate delta delta Ct as an exponent of 2 (2^ΔΔCT^) with ΔCt=CtnDNA−CtmtDNA.

Preparation of Heart Proteins
-----------------------------

For the preparation of heart homogenates, mice were killed with carbon dioxide, exsanguinated and the whole organs immediately minced and homogenized on ice in 5 volumes of ice-cold homogenization buffer (HB: 20 mmol/L HEPES, pH7.4, 250 mmol/L sucrose, 1 mmol/L EDTA, 0.1 mmol/L PMSF) by using 10 strokes in a tight fit glass/glass homogenizer. Cytosolic and mitochondrial fractions were separated as previously described.[@b23] Protein concentration was determined by Bradford assay.

Western Blotting
----------------

Proteins were fractionated by SDS-PAGE and transferred onto a nitrocellulose membrane (Schleicher & Schuell Bioscience). The blot was blocked (1 hour at room temperature) with TBST (Tris-buffered saline, 0.1% Tween-20) containing 5% nonfat milk and then probed with the primary antibodies, in the following dilutions: 1:500 anti-TXNRD2 (Atlas Antibodies), 1:1000 anti-TXNRD2 (clone 1C4 as described earlier[@b24]), 1:10 000 anti-ACTIN (Sigma), 1:5000 anti-catalase (Sigma), 1:500 anti-LC3B (Sigma), 1:2000 anti-HSP60 (BD Bioscience), 1:5000 anti-HSP25 (Biomol GmbH), 1:500 anti--hypoxia inducible factor 1, α subunit (HIF1α) (Santa Cruz Biotechnology,), and 1:1000 anti-p62/SQSTM1 (Sigma). After washing with TBST (2×15 minutes), immunodetection of the signals was performed by using horseradish peroxidase--conjugated, corresponding secondary antibodies followed by 2 additional washing steps (2×10 minutes). Finally, the signal was detected by using ECL Plus Detection Reagent (Amersham Biosciences). Protein expression was quantified by using ImageJ software (National Institutes of Health).

Histology and Immunohistochemistry
----------------------------------

Mice were sacrificed with carbon dioxide. Hearts were immediately excised, arrested with 1M KCl, weighed, fixed in 4% paraformaldehyde for 24 hours, and embedded in paraffin. Serial 5 μm sections were stained with hematoxylin and eosin. For immunohistochemistry, heat-induced epitope retrieval with the use of 0.01 mol/L sodium citrate was applied. Primary antibody dilution for anti--lysosome-associated membrane protein 1 (LAMP1) (Santa Cruz Biotechnology) was 1:500. Five representative images of LAMP1-stained sections were acquired from each heart of 3 animals per genotype. Number of LAMP1-positive vesicles was analyzed in all images by using Fiji software.[@b25] For histological examination of collagen content (cardiac fibrosis), tissue was embedded in paraffin, cut into 4- to 10-μm sections, and stained with Masson trichrome. Two blinded observers scored the level of fibrosis on a scale from 0 to 3 in 9 animals per genotype. For the detection of apoptotic nuclei, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed on paraffin sections according to the manufacturer's protocol (in situ Cell Death Detection Kit, POD; Roche Diagnostics GmbH).

Quantification of Vacuolization
-------------------------------

For determination of the severity of vacuolization in the myocardium, horizontal hematoxylin and eosin--stained paraffin sections were analyzed by 2 operators blinded to specimen origin. Per genotype (n=10), 2 consecutive sections were graded as follows: no vacuolization (0), discrete (1) if only focal vacuoles were present, moderate (2) if multifocal vacuolization was present, and intense (3) if diffuse vacuolization was present.

Mitochondrial Respiration
-------------------------

Mitochondria were isolated by the use of differential centrifugation. Briefly, freshly removed hearts were minced by using a razor blade and homogenized in ice-cold isolation buffer (IB: 5 mmol/L TES, 0.3 mmol/L sucrose, 0.2 mmol/L EGTA, pH 7.2, with KOH) by using 7 strokes in a tight-fit glass/glass homogenizer. Homogenates were cleared from debris and nuclei via centrifugation (700*g*, 10 minutes, 4°C), mitochondria were pelleted (11 000*g*, 15 minutes, 4°C), washed twice (11 000*g*, 10 minutes, 4°C), and resuspended in IB. Protein concentrations were determined with Bradford assay. Quality and purity were confirmed by immunoblotting the different fractions with the use of anit-GRP78 (endoplasmic reticulum marker) and anti-VDAC1 (mitochondrial marker) antibodies. Anti-VDAC1 and anti-MnSOD Western blots verified comparable mitochondrial content in the protein fractions. O~2~ consumption and functional integrity of these mitochondria were assessed with the use of respiratory measurements in a Clark-type oxygen electrode (Oxygraph; Hansatech Instruments Ltd) as described previously[@b26] (0.25 mg/mL in respiration buffer: 0.14 mol/L mannitol, 0.05 mol/L sucrose, 5 mol/L MgCl~2~, 0.25 mmol/L EDTA, 0.01 mol/L phosphate, 2 mmol/L Tris-HCl, pH 7.4, at 30°C with 8 mmol/L succinate).

Transmission Electron Microscopy
--------------------------------

The left ventricle was cut into 1-mm^2^ cubes and fixed with 3% glutaraldehyde in 0.1 mol/L cacodylate. Samples were postfixed in 1% OsO~4~ (4°C, 1 hour), washed 3×, dehydrated in alcohol, and embedded in Eponate. Semithin sections were stained with toluidine blue and scored by a blinded operator. Ultrathin sections were cut on the ultramicrotome, stained with uranyl acetate followed by lead citrate, and viewed with a Zeiss EM 10 CR transmission electron microscope.

ATP and GSH Measurement
-----------------------

Frozen heart tissue was weighed and homogenized on liquid nitrogen in a medium containing 20 mmol/L HEPES, pH 7.4, 250 mmol/L sucrose, and 1 mmol/L EDTA. For ATP measurement, the homogenate was heated immediately for 5 minutes on 95°C, cooled down on ice for 5 minutes, and centrifuged for 2 minutes at 13 000*g* on 4°C. With 50 μL of the supernatant, an ATP assay (ATP Bioluminescence Assay Kit CLS II; Roche) was performed according to the manufacturer's instructions. For reduced glutathione (GSH) measurement, the homogenate was deproteinated by using metaphosphoric acid and assayed according to the enzymatic recycling method.[@b27]

ROS Assay
---------

The production of radical species in isolated mitochondria, challenged by different chemicals, was essentially measured as described.[@b28] Briefly, freshly isolated mitochondria were stained for 10 minutes at 0°C with 2′,7′-dichloro-dihydro-fluorescein-diacetate (D-399; Invitrogen GmbH)[@b29],[@b30] in IB. After a washing step, stained mitochondria were incubated in swelling buffer (SB: 0.2 mol/L sucrose, 10 mmol/L MOPS-Tris, 5 mmol/L succinate, 1 mmol/L H~3~PO~4~, 10 μmol/L EGTA, 2 μmol/L rotenone) with the diverse chemicals, and the development of radical species was followed by the fluorescence of dichlorofluorescein[@b31] (Ex 485/20; Em 528/20).

Metabolite Quantification
-------------------------

The targeted metabolomic approach was based on electrospray ionization--liquid chromatography (LC)-mass spectrometry (MS)/MS measurements by using the Absolute*IDQ* kit p180 (BIOCRATES Life Sciences AG), allowing simultaneous quantification of 186 metabolites. Heart muscle was homogenized in phosphate buffer (3 μL/mg).[@b32]--[@b34] Sample handling was performed with a Hamilton Microlab STAR robot (Hamilton Bonaduz AG) and an Ultravap nitrogen evaporator (Porvair Sciences), in addition to standard laboratory equipment. MS analyses were performed with an API 4000 LC/MS/MS System (AB Sciex Deutschland GmbH) equipped with a 1200 Series HPLC (Agilent Technologies Deutschland GmbH) and an HTC PAL auto sampler (CTC Analytics) controlled with use of the software Analyst 1.5. Data evaluation for quantification of metabolite concentrations and quality assessment were performed with the Met*IDQ* software package, which is an integral part of the Absolute*IDQ* kit. Internal standards serve as reference for the calculation of metabolite concentrations \[μmol/L\].

Statistical Analysis
--------------------

Results are shown as mean±SD values (n=number of animals or experiments as indicated, sample sizes are given per group being compared). Comparisons between groups were performed by using the unpaired, 2-tailed Student *t* test. The paired *t* test was used when appropriate as indicated in the text. Due to small sample size (n=3), we did not apply statistical tests on quantification of mRNA- and protein-expression data. Statistical significance was defined as *P*\<0.05 (\*), *P*\<0.01 (\*\*), or *P*\<0.001 (\*\*\*).

The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.

Results
=======

Tamoxifen-Induced Heart-Specific Knockout of *Txnrd2* in Adult Mice
-------------------------------------------------------------------

Inducible heart-specific *Txnrd2-*deficient mice were generated as described.[@b15] Mice carrying floxed *Txnrd2* alleles (*Txnrd2*^*fl/fl*^)[@b12] were mated to heterozygous *Txnrd*^*+/−*^ mice carrying a cardiomyocyte-specific *MerCreMer* transgene.[@b14] The resulting *Txnrd2*^*−/fl,Tg\[MerCreMer\]*^ mice and *Txnrd2*^*+/fl,Tg\[MerCreMer\]*^ littermates are hereafter referred to as KOs (*Txnrd2*^*−/−*^) and controls (ctrl) (Figure[1A](#fig01){ref-type="fig"}). Animals were fed tamoxifen for 5 weeks starting at the age of 6 weeks for KO induction, and all time points reported hereafter refer to the end of tamoxifen administration (week 0) (Figure[1B](#fig01){ref-type="fig"}). Experiments were carried out by using young (aged 5 to 6 months) (Y), middle-aged (aged 10 to 14 months) (MA), and old (aged 18 to 19 months) (O) mice as indicated. Tamoxifen administration led to a reduction in *Txnrd2* mRNA concentrations by 70±9% (n=3) and a substantial reduction in TXNRD2 protein levels in whole heart preparations of KO animals compared with controls (Figure[1C](#fig01){ref-type="fig"}, [1D](#fig01){ref-type="fig"}, and [1E](#fig01){ref-type="fig"}).

![Reduction of cardiac *Txnrd2* expression by tamoxifen administration. A, Generation of *Txnrd2*^*−/fl;Tg\[MerCreMer\]*^ (knockout, ko) and *Txnrd2*^*+/fl;Tg\[MerCreMer\]*^ (control, ctrl) mice. B, To inactivate *Txnrd2*, 6-week-old ko and ctrl mice were treated with tamoxifen for 5 weeks. The end of tamoxifen treatment was defined as week 0. C, Semiquantitative RT-PCR 4 weeks after feeding tamoxifen-containing diet confirmed reduction of *Txnrd2*mRNA. D, Reduced *Txnrd2*mRNA shown by RT-PCR of whole heart cDNA. mRNA expression was normalized to *Gapdh*. Each column represents 3 independent cDNA samples (n=3). E, Reduced TXNRD2 expression in Western blot of cytosolic and mitochondrial protein fractions from whole hearts. ACTIN served as cytosolic and VDAC1 as mitochondrial loading control. αMHC indicates alpha-myosin heavy chain; RT-PCR, real-time polymerase chain reaction; TXNRD2, thioredoxin reductase 2; VDAC1, voltage-dependent anion-selective channel protein 1.](jah30004-e002153-f1){#fig01}

Impaired LV Function in *Txnrd2*^*−/−*^ Mice
--------------------------------------------

Assessment of LV function by echocardiography revealed LV dysfunction in *Txnrd2*^*−/−*^ hearts. LVESD values were significantly increased in KO animals (MA: 3.17±0.65 mm; O: 3.22±0.49 mm) compared with controls (MA: 2.39±0.3 mm; O: 2.61±0.4 mm) (MA: *P*\<0.01; O: *P*\<0.01) at both time points tested, whereas LVEDD values did not differ significantly (Figure[2A](#fig02){ref-type="fig"} and [2B](#fig02){ref-type="fig"}). Accordingly, LV end-systolic volume (LVESV) values were significantly increased in KO animals (MA: 42.40±20.13 mm^3^; O: 43.01±51.19 mm^3^) compared with controls (MA: 20.51±6.49 mm^3^; O: 25.18±9.85 mm^3^) (MA: *P*\<0.01; O: *P*\<0.01), whereas LV end-diastolic diameter (LVEDV) values did not differ significantly (Figure[2C](#fig02){ref-type="fig"} and [2D](#fig02){ref-type="fig"}).

![Impaired left ventricular function in *Txnrd2*^−/−^ hearts. Results from, Echocardiography (A through G) and noninvasive measurement of blood pressure (H and I) are shown. A through G, n≥8; H and I, n=9. Time points as indicated below *x*-axis. ctrl indicates control; DBP, diastolic blood pressure; EF, ejection fraction; FS, fractional shortening; ko, knockout; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; MA, middle-aged; O, old; SBP, systolic blood pressure; *Txnrd2*, thioredoxin reductase 2.](jah30004-e002153-f2){#fig02}

Fractional shortening was significantly reduced in KO animals versus controls (20.58±5.50% \[MA\] and 20.64±3.86% \[O\] versus 36.40±3.35% \[MA\] and 37.29±5.52% \[O\]; MA: *P*\<0.001; O: *P*\<0.001) (Figure[2E](#fig02){ref-type="fig"}). Also, LV ejection fraction was reduced significantly in KO animals versus controls (42.20±9.74% \[MA\] and 42.39±7.22% \[O\] versus 66.78±4.36% \[MA\] and 67.26±7.39% \[O\]; MA: *P*\<0.001; O: *P*\<0.001) (Figure[2F](#fig02){ref-type="fig"}). Heart rate was slightly higher in KO animals versus controls (557±47 min^−1^ \[MA\] and 467±33 min^−1^ \[O\] versus 497±61 min^−1^ \[MA\] and 441±44 min^−1^ \[O\]) (Figure[2G](#fig02){ref-type="fig"}). This increase was significant in middle-aged mice (*P*\<0.05).

Reduced Blood Pressure in *Txnrd2*^*−/−*^ Mice
----------------------------------------------

Noninvasive measurements of blood pressure revealed a significant (*P*\<0.05) decrease in systolic (91±7.7 mm Hg in KO versus 99.6±6.7 mm Hg in controls) and diastolic blood pressure (83.2±7.0 mm Hg in KO versus 90.1±5.6 mm Hg in controls) in KOs (Figure[2H](#fig02){ref-type="fig"} and [2I](#fig02){ref-type="fig"}).

Gross Morphological Heart Alterations in Aged *Txnrd2*^*−/−*^ Mice
------------------------------------------------------------------

In young mice, heart-to-body weight ratio in KOs (5.1±0.7 mg/g) was similar to that in controls (5.3±0.8 mg/g) (*P*=0.98), whereas in middle-aged mice, the heart-to-body weight ratio of KO animals was increased by ≈14% (5.6±0.7 mg/g for KO and 4.9±0.7 mg/g for controls, *P*\<0.001) and by ≈6% in old mice (5.4±0.7 mg/g for KO and 5.1±0.6 mg/g for controls, *P*\<0.05), indicating a mild hypertrophic response. Body weight was not altered significantly in KOs versus controls (Figure[3G](#fig03){ref-type="fig"}). Gross morphological analysis revealed enlargement of KO hearts only in rare cases (Figure[3A](#fig03){ref-type="fig"} versus [3B](#fig03){ref-type="fig"}, Figure[3E](#fig03){ref-type="fig"} and [3F](#fig03){ref-type="fig"}). Histological analysis showed LV hypertrophy (Figure[3C](#fig03){ref-type="fig"} versus [3D](#fig03){ref-type="fig"}) in these *Txnrd2*^*−/−*^ mice. Appearance, behavior, and spontaneous mortality (Figure[3H](#fig03){ref-type="fig"}) of *Txnrd2*^*−/−*^ mice were indistinguishable those of from age-matched controls during the observation period.

![Gross morphological alterations in *Txnrd2*^*−/−*^ hearts. Representative hearts of old control (A and C) and knockout mice (B and D) are shown. A and B, hearts were photographed after fixation. Appearance of *Txnrd2* knockout hearts varied, in rare cases a similar enlargement as shown in the example on the right was observed, indicating a hypertrophic response. C and D, coronary sections of the same hearts as in (A and B) were stained with H&E showing left ventricular concentric hypertrophy. Magnifications: A and B, ×6; C and D, ×8. E and F, hearts were photographed after dissection. Hearts shown in F are the same specimens as shown in (B). G, Analysis of HW and BW are shown, (G), n≥20. H, Kaplan--Meier plot showing spontaneous mortality in *Txnrd2*^*−/−*^ mice compared with controls. Only individuals that died spontaneously after knockout induction within experimental groups are shown. Knockout and control animals were aged for the respective experiments and spontaneous mortality was recorded: 9% (15 of 164 individuals) for knockouts and 10% (23 of 219 individuals) for controls. \**P*\<0.05, \*\**P*\<0.01. BW indicates body weight; H&E, hematoxylin and eosin; HW, heart weight; MA, middle-aged; O, old; *Txnrd2*, thioredoxin reductase 2; Y, young.](jah30004-e002153-f3){#fig03}

HIF1α Protein Stabilization in *Txnrd2*^*−/−*^ Hearts
-----------------------------------------------------

It has been shown that the mitochondrial thioredoxin system can potentially influence HIF1α protein levels.[@b35] Indeed, immunoblotting analysis for HIF1α detected increased protein levels of splice variant HIF1α-I.1 in KO hearts in middle-aged and old mice (≈10-fold, n=3) (Figure[4A](#fig04){ref-type="fig"}). These data indicate an HIF1α protein stabilization, as *Hif1a* mRNA was not changed significantly (Figure[4B](#fig04){ref-type="fig"}).

![*Txnrd2* deletion induced HIF1a stabilization and transcriptional signature. A, Western blot (top) and quantification (bottom) showing HIF1a stabilization in knockouts, using control (c) and knockout (k) heart homogenates from MA and O mice probed with anti-TXNRD2 and anti-HIF1α antibodies. An unspecific band served as loading control. B, Alterations in relative gene expression determined by RT-PCR in *Txnrd2*^−/−^ hearts of middle-aged (MA) and old (O) mice. Genes involved in oxidative stress response (i), HIF1 target genes (ii), markers for oxidative phosphorylation (iii), potential mediators of uncoupling (iv), and for LV dysfunction (v) in *Txnrd2*^−/−^ hearts relative to controls. Values are the fold change in mRNA transcript level of at least 4 independent cDNA samples (n≥4) relative to control (set as 1). All probes were normalized to *Actin*. \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.001. LV indicates left ventricular; MA, middle-aged; O, old; RT-PCR, real-time polymerase chain reaction; *Txnrd2*, thioredoxin reductase 2.](jah30004-e002153-f4){#fig04}

Transcriptional Signature Induced by *Txnrd2* Ablation
------------------------------------------------------

HIF1α target genes and markers for oxidative phosphorylation, mitochondrial biogenesis, oxidative stress response, and uncoupling proteins and for LV dysfunction were quantified by using RT-PCR (Figure[4B](#fig04){ref-type="fig"}). While the HIF1α target genes *Vegfa* and *Bnip3* were found unchanged, *Glut-1* was induced significantly in middle-aged and old mice (MA: +52%, *P*\<0.05; O: +75%, *P*\<0.05). Moreover, a significant decrease was observed in fatty acid catabolism--related genes in old mice (O: *Pgc1a*, −64%, *P*\<0.01; *Ppara*, −52%, *P*\<0.001; *Cd36*, −49%, *P*\<0.01; *Acadm*, −53%, *P*\<0.001). In accordance with this, the expression of acyl-coenzyme A thioesterase 2 (*Acot2*), which typically avoids degradation of activated fatty acids by β-oxidation, was upregulated at both time points (MA: +135%, *P*\<0.01; O: +314%, *P*\<0.05). On the contrary, markers for glucose oxidation were differentially regulated (MA: *Pdk4*, +115; *P*\<0.05; O: *Pdha1*, −45%, *P*\<0.01). Importantly, genes involved in mitochondrial biogenesis and electron transfer were downregulated significantly in KO hearts from old mice (O: *Tfam*, −48%, *P*\<0.01; *Pgc1a*, −64%, *P*\<0.01; *Etfdh*, −48%, *P*\<0.01), whereas uncoupling proteins 2 was upregulated (MA: +80% *P*\<0.05; O: +46%, *P*\<0.01). Hypertrophy markers (MA: *Bnp*, +128%, *P*\<0.05; O: *Anp*, +324%, *P*\<0.05%; *Bnp*, +193%, *P*\<0.05) were strongly upregulated in *Txnrd2*^*−/−*^ hearts at both time points (Figure[3B](#fig03){ref-type="fig"}). Altogether, expression analysis suggests an altered metabolism in *Txnrd2*^*−/−*^ hearts, specifically fatty acid metabolism. Because mitochondria are one of the major sites of FA catabolism, this indicates mitochondrial dysfunction.

Mitochondrial Degeneration in *Txnrd2*^*−/−*^ Cardiomyocytes
------------------------------------------------------------

Cellular alterations became obvious in toluidin blue--stained semithin sections of *Txnrd2*^*−/−*^ myocardium in middle-aged mice. In all cardiomyocytes of control animals, mitochondria were clearly visible and formed a characteristic distribution pattern (Figure[5A](#fig05){ref-type="fig"}, arrowheads). In contrast, in 37±13% of the KO cardiomyocytes, mitochondria and their distribution pattern were not discernible, indicating mitochondrial depletion (*P*\<0.001, Figure[5B](#fig05){ref-type="fig"} and [5C](#fig05){ref-type="fig"}). In the cytoplasm of these KO myocytes, dark-blue--stained granular deposits were visible (Figure[5B](#fig05){ref-type="fig"}, arrows). The number of these granular deposits was significantly higher in KO hearts (76.3±54.3 for KO versus 3.3±3.5 for controls, *P*\<0.001) (Figure[5D](#fig05){ref-type="fig"}).

![Presence of degenerated mitochondria in *Txnrd2*^−/−^ myocardium of middle-aged mice. A, Toluidin-blue--stained semithin sections showing clearly structured mitochondria (arrowheads) in the CP of control cardiomyocytes (N=nucleus). B, Knockout hearts display myocytes with normal mitochondria alternating with myocytes containing degenerated mitochondria (broken line) and dark-stained globular structures (arrows). C, Fraction of cells containing degenerated mitochondria (n=22 \[control\] and n=25 \[knockout\] microscopic fields, 2 individuals each, total number of cells counted: 718 \[controls\] and 1017 \[knockouts\]). D, Number of granules per microscopic field in all cells (n=12 \[control\] and n=16 \[knockout\] microscopic fields, 2 individuals each). Magnification: ×100. E through K, Transmission electron micrography of the same specimens as in (A and B). E, Control myocardium shows normal myocytes containing mitochondria (Mt) of normal structure, myofibrils (Mf) and few distinct lysosomes (Ly) in the perinuclear region. F and G, knockout cardiomyocytes showing disorganized mitochondrial structures and accumulation of electron-dense and electron-light bodies (lysosome-like organelles, arrowheads). H, higher magnifications of control mitochondria. I, knockout cardiomyocytes with degenerating mitochondria (Mt\*) and mitochondria containing dense bodies. Electron-light (J) and electron-dense (K) structures in close vicinity within the same cell consistent with lipofuscin accumulation. A through E, n=2 males and 2 females per genotype. Magnification: E through G, ×2520; H through K, ×20 000. L and M, mitochondrial DNA set into relation to nuclear DNA as a standard. \*\*\**P*\<0.001. CP indicates cytoplasm; *Txnrd2*, thioredoxin reductase 2.](jah30004-e002153-f5){#fig05}

Transmission electron microscopy confirmed the results obtained from semithin sections. In control mice, mitochondria showed typical age-appropriate morphology and normal cytoplasmatic distribution pattern. Few distinct lysosomes were present in the perinuclear region (Figure[5E](#fig05){ref-type="fig"}). At higher magnification, the mitochondrial matrix in controls was of homogeneous density without signs of degeneration (Figure[5H](#fig05){ref-type="fig"}). In contrast, KO cardiomyocytes showed disorganized mitochondrial structures (Figure[5F](#fig05){ref-type="fig"}). Ultrastructural changes included loss of cristae and matrix homogeneity (Figure[5I](#fig05){ref-type="fig"}). Globular bodies, characterized by increased osmophilia at their periphery, were frequently associated with degenerating mitochondria (Figure[5I](#fig05){ref-type="fig"}). The cytoplasm of KO cardiomyocytes contained numerous lysosome-like organelles showing different morphologies in size, content, and electron density (Figure[5F](#fig05){ref-type="fig"} and [5G](#fig05){ref-type="fig"}, arrowheads). These lysosome-like organelles exhibited electron-dense regions alternating with lucid regions, which indicated lipofuscin accumulation (Figure[5J](#fig05){ref-type="fig"}), or a homogeneous dense matrix (Figure[5K](#fig05){ref-type="fig"}). Signs of fibrosis, apoptosis, or inflammation were absent.

Despite mitochondrial degeneration, relative myocyte mtDNA content was not altered in KO hearts of middle-aged mice (1.09±0.26 for KO and 1.0 for controls, *P*=0.36) (Figure[5L](#fig05){ref-type="fig"}), while it was significantly reduced in old mice by 29% (0.71±0.15 for KO and 1.0 for controls, *P*\<0.001) (Figure[5M](#fig05){ref-type="fig"}).

Myocardial Degeneration and Increased Autophagic Activity in *Txnrd2*^*−/−*^ Myocardium
---------------------------------------------------------------------------------------

Hematoxylin and eosin staining of hearts from old control mice revealed few cardiomyocytes showing cytoplasmic vacuolization. In contrast, myocardial vacuolization was 4.5-fold higher in old KO mice (2.7±0.5 for KO and 0.6±0.7 for controls, *P*\<0.001) (Figure[6A](#fig06){ref-type="fig"} through [6C](#fig06){ref-type="fig"}). No cell infiltrates indicative of inflammation were visible. Ultrastructural analysis at the same time point confirmed the severe mitochondrial degeneration and vacuolization in KOs (Figure[6D](#fig06){ref-type="fig"} versus [6E](#fig06){ref-type="fig"}). Moreover, different states of autophagic degradation were present in KO cardiomyocytes, such as vacuoles sequestering dense cytoplasm (Figure[6F](#fig06){ref-type="fig"}), designated autophagosomes, or single-membrane--bound vacuoles containing remnants of membranes and degraded cellular material (Figure[6G](#fig06){ref-type="fig"}). Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a marker of autophagic activity.[@b36] Western blot analysis revealed a ≈2-fold stronger 18-kDa LC3-I signal, while the LC3-II signal was not consistently increased (Figure[6H](#fig06){ref-type="fig"} and 6I). Moreover, the protein amount of p62, being also involved in autophagosome formation,[@b37] was markedly upregulated in KOs (≈3.8-fold). Additionally, *p62* mRNA levels were significantly higher in KO hearts (p62: control set to 1 and 2.17±0.71 for KO, *P*\<0.01) (Figure[6H](#fig06){ref-type="fig"} through [6J](#fig06){ref-type="fig"}). Immunostaining of lysosome-associated membrane protein 1 (LAMP1), a lysosomal marker, was significantly increased in KO hearts (Figure[7A](#fig07){ref-type="fig"} through [7C](#fig07){ref-type="fig"}). Masson trichrome staining showed no increase in interstitial fibrosis in young or old *Txnrd2*^*−/−*^ mice (Figure[7D](#fig07){ref-type="fig"} through [7F](#fig07){ref-type="fig"}). Consistently, TUNEL staining failed to detect an increase in TUNEL-positive apoptotic nuclei in the KO myocardium (Figure[8](#fig08){ref-type="fig"}).

![Autophagy in hearts of old *Txnrd2*^*−/−*^ mice. Representative transverse sections obtained from old control (A and D), and knockout hearts (B, E, F and G). A and B, paraffin sections stained with hematoxylin and eosin. Note the markedly vacuolated cytoplasm in the knockout (B). C, quantification of vacuolization. D through G, Electron micrographs demonstrating severe mitochondrial degeneration in knockouts (E). Presence of double-membrane autophagosomes (F) and autolysosomes containing cellular material (G) in knockout cardiomyocytes (n=2). H and I, Western blots using protein homogenates obtained from 3 control (c1 to c3) and 3 knockout (k1 to k3) hearts of old mice probed with anti-LC3 and anti-p62 antibodies and corresponding quantification of protein expression. ACTIN was used as standard. J, Increased *p62*mRNA expression as analyzed by real-time RT-PCR, relative to control (set as 1). mRNA expression was normalized to *Actin*. *Txnrd2-*specific primers were used as internal control (*P*\<0.01, n=6). Magnification: A and B, ×20; D and E, ×12 600; F and G, ×20 000. \*\**P*\<0.01, \*\*\**P*\<0.001. LC3 indicates microtubule-associated protein 1A/1B-light chain 3; RT-PCR; real-time polymerase chain reaction; *Txnrd2*, thioredoxin reductase 2.](jah30004-e002153-f6){#fig06}

![Increase of Lamp1 in hearts of old *Txnrd2*^*−/−*^ mice. Representative transverse paraffin sections obtained from 3 control (c1 to c3) (A) and 3 knockout (k1 to k3) hearts (B) stained with LAMP-1 antibody, indicating enhanced lysosomal activity in knockouts. Each image represents one individual. Note the markedly vacuolated myocardium in the knockout samples (B). C, Quantification of LAMP1-positive vesicles (5 images per animal, n=3 per genotype). Magnification: A and B, ×40. D and E, Masson's Trichrome staining in *Txnrd2*^*−/−*^ hearts. Representative transverse paraffin sections obtained from control (A) and knockout (B) hearts from old mice are shown, after Masson's Trichrome staining had been performed. No increase in collagen deposits was observed in knockout specimens compared with controls. F, Quantification of level of fibrosis, n=9 per genotype. Magnification: A and B, ×40. \**P*\<0.01. LAMP1 indicates lysosomal-associated membrane protein 1; *Txnrd2*, thioredoxin reductase 2.](jah30004-e002153-f7){#fig07}

![TUNEL staining in thioredoxin reductase 2 (*Txnrd2*^*−/−*^) hearts. Representative transverse paraffin sections obtained from knockout hearts of old mice are shown. Sections were stained with hematoxylin and eosin (A) and consecutive sections were used for TUNEL staining (B). Throughout the myocardium vacuoles are detectable (arrows in A), in the consecutive sections no TUNEL-positive nuclei are detectable. Paraffin sections of testis were used as positive control for TUNEL staining (C). Magnification: A and B, ×20. TUNEL indicates terminal deoxynucleotidyl transferase dUTP nick end labeling.](jah30004-e002153-f8){#fig08}

These results indicate that autophagic activity is deregulated in aged *Txnrd2*^*−/−*^ cardiomyocytes and emphasizes the cellular stress situation found in aged KO hearts.

Decreased Oxygen Consumption of TXNRD2-Deficient Mitochondria
-------------------------------------------------------------

Mitochondrial oxygen (O~2~) consumption ([Vo]{.smallcaps}~2~) was analyzed in isolated heart mitochondria (Figure[9A](#fig09){ref-type="fig"} and [9B](#fig09){ref-type="fig"}). Unaltered VDAC1 amount in these samples, as analyzed with Western blotting, demonstrated that equal amounts of mitochondria were used (data not shown). A significantly lower O~2~ consumption in isolated KO compared with control mitochondria was observed at both time points applying the paired *t* test (Figure[9A](#fig09){ref-type="fig"} and [9B](#fig09){ref-type="fig"}, succinate-stimulated respiration \[in nmol/mL per minute\]: MA: 10.7±4.7 in KO versus 17.2±7.0 in controls, *P*\<0.05; O: 13.5±3.4 in KO versus 18.7±5.0 in controls, *P*\<0.05; ADP-stimulated respiration: MA: 22.8±9.4 in KO versus 36.3±14.6 in controls, *P*=0.09; O: 31.3±7.1 in KO versus 40.4±6.4 in controls, *P*\<0.01; succinate-stimulated respiration in the presence of oligomycin and ADP: MA: 8.5±3.7 in KO versus 18.7±8.7 in controls, *P*=0.09; O: 21.4±8.5 in KO versus 26.2±8.7 in controls, *P*\<0.05). Mitochondrial membrane integrity, however, as determined by the succinate-dependent respiratory control ratios was not compromised in KO mitochondria (Figure[9B](#fig09){ref-type="fig"}, MA: 2.3±0.4 in KO versus 2.1±0.2 in controls; O: 2.7±0.7 in KO versus 2.5±0.6 in controls). This comparable mitochondrial coupling coincided with equal ATP amounts in control and KO myocardia (Figure[9C](#fig09){ref-type="fig"}, MA: 16.5±9.2 in KO versus 18.5±17.2 in controls; O: 13.5±11.0 in KO versus 13.7±9.2 in controls). These data demonstrate that loss of *Txnrd2* impairs mitochondrial function, suggesting reduced oxidative phosphorylation.

![Membrane integrity and decreased respiration of residual mitochondria. A, Exemplary recordings of O~2~ consumption by mitochondria isolated from control and knockout hearts of old mice. The graphs show 2 consecutive measurements performed at the same day. Addition of mitochondria, rotenone, succinate, ADP, and oligomycin to the assay as indicated by arrows. B, Decreased mitochondrial O~2~ consumption rates ([Vo]{.smallcaps}~2~) of mitochondria isolated from control and knockout hearts of MA (n=3) and O mice (n=7). V~succ~: respiration in the presence of the substrate succinate (succ); V~ADP~: respiration in the presence of succinate plus ADP; V~Oligo~: respiration while ATP synthesis was blocked by oligomycin, an inhibitor of ATP synthase. Identical RCRs calculated as V~ADP~:V~succ~ show membrane integrity and absence of uncoupling in MA (n=4) and O (n=7) mice. C, ATP amounts measured in myocardium from MA and O knockout mice compared with controls (n=4). \**P*\<0.05, \*\**P*\<0.01. MA indicates middle-aged; O, old; RCRs, respiratory control ratios.](jah30004-e002153-f9){#fig09}

Mitochondrial ROS Production and Induction of Antioxidative Systems
-------------------------------------------------------------------

Lower O~2~ consumption indicates the possibility of higher ROS production, as mitochondria produce ROS especially under decreased O~2~ consumption.[@b38] We therefore assessed overall ROS production. In agreement, mitochondrial ROS production in old mice, measured in parallel on the same samples shown in Figure[9B](#fig09){ref-type="fig"} by using different stressors, was increased in KO mitochondria compared with controls (Figure[10A](#fig10){ref-type="fig"}). Although the increase in ROS production did not reach statistical significance when applying the paired *t* test, it was highly reproducible under different conditions tested. Basal ROS production of KO mitochondria incubated in isolation buffer was heightened by ≈1.27-fold (746±159 in KO versus 589±127 in controls). Challenging mitochondria by the addition of 100 μmol/L Ca^2+^, 50 μmol/L Hg^2+^ or 100 μmol/L tertiary butylhydroperoxide (tBuOOH) did increase ROS, but the difference in ROS production between KOs and controls remained unchanged (Ca^2+^: 802±207 in KO versus 559±127 in controls; Hg^2+^:1323±384 in KO versus 987±353 in controls; tBuOOH: 1879±469 in KO versus 1414±474 in controls).

![Increased mitochondrial ROS production in vitro and upregulation of antioxidative systems in vivo. A, Increased basal mitochondrial ROS production in knockouts measured by endpoint fluorescence after 60 minutes in vitro. Isolated mitochondria were untreated (Buffer) or stressed with 100 μmol/L calcium (Ca^+2^), with or without CsA, 50 μmol/L mercury (Hg^2+^) or 100 μmol/L tBuOOH (n=4). B, Amount of reduced (GSH) and oxidized glutathione (GSSG) measured in knockout myocardium from MA and O knockout mice compared with controls (n=4). C, Western blots using protein homogenates from 3 control (c1 to c3) and 3 knockout (k1 to k3) hearts probed with anti-HSP25, anti-HSP60, anti-CAT or anti-ACTIN (loading control) antibody. D, quantification indicating a stress response in knockouts. \**P*\<0.05. CAT indicates catalase; CsA, cyclosporine A; GSH, reduced glutathione; GSSG, oxidized GSH.; MA, middle-aged; O, old; ROS, reactive oxygen species; tBuOOH, tertiary butylhydroperoxide.](jah30004-e002153-f10){#fig10}

GSH levels (in nmol/mg protein) were significantly increased in KO myocardium at both time points (MA: 364.75±60.78 in KO versus 274.30±40.55 in controls, *P*\<0.05; O: 292.33±29.93 in KO versus 227.16±26.98 in controls, *P*\<0.05). As oxidized GSH (GSSG) levels were also increased, GSH/GSSG ratio was not altered (Figure[10B](#fig10){ref-type="fig"}).

Amounts of the stress-induced proteins HSP25 and HSP60 were ≈1.6-fold higher in KO hearts from old mice. The amount of catalase protein was ≈1.9-fold greater in KOs (Figure[10C](#fig10){ref-type="fig"} and [10D](#fig10){ref-type="fig"}). These data support the hypothesis that increased ROS production is compensated in vivo by a cytoprotective response.

Metabolic Signature Induced by *Txnrd2* Ablation
------------------------------------------------

With use of a quantitative mass spectroscopic approach, amino acids (AAs), acyl-carnitines, biogenic amines, and hexoses were measured in the myocardia of old mice (Figure[1](#fig01){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}).

###### 

List of Acyl-carnitines, Amino Acids, Biogenic Amines, and Sugar Included in This Study

  Analyte Description   Control                                                                            Knockout                                      *P* Value                                                                                             
  --------------------- ---------------------------------------------------------------------------------- --------------------------------------------- ----------- ----------------------------------------- ------------------------------------- --------- -------
                        Calculated total carnitine (C0 to C18)                                             143.83                                        26.740      160.99                                    25.590                                          
                        Calclated total acyl-carnitines (C2 to C18)                                        40.06                                         7.631       31.81                                     9.145                                 0.01      
                        Acyl/free ratio                                                                    0.392                                         0.073       0.254                                     0.082                                 \<0.001   
                        Summed short-chain acyl-carnitines (C3 to C5)                                      2.568                                         0.6889      3.312                                     0.8628                                0.01      
                        Summed medium-chain acyl-carnitines (C6 to C12)                                    6.000                                         0.200       0.680                                     0.148                                           
                        Summed long-chain acyl-carnitines (C14 to C18)                                     0.6502                                        0.3473      0.5409                                    0.2713                                          
  Acyl-carnitines       C0                                                                                 [dl]{.smallcaps}-Carnitine (free carnitine)   104         21.5                                      129[‡](#tf1-4){ref-type="table-fn"}   26.5      0.009
  C10                   Decanoyl-[l]{.smallcaps}-carnitine                                                 0.068[\*](#tf1-2){ref-type="table-fn"}        0.029       0.071[\*](#tf1-2){ref-type="table-fn"}    0.017                                           
  C10.1                 Decenoyl-[l]{.smallcaps}-carnitine                                                 0.067[\*](#tf1-2){ref-type="table-fn"}        0.032       0.076[\*](#tf1-2){ref-type="table-fn"}    0.026                                           
  C10.2                 Decadienyl-[l]{.smallcaps}-carnitine                                               0.025[\*](#tf1-2){ref-type="table-fn"}        0.013       0.031[\*](#tf1-2){ref-type="table-fn"}    0.010                                           
  C12                   Dodecanoyl-[l]{.smallcaps}-carnitine                                               0.042[\*](#tf1-2){ref-type="table-fn"}        0.019       0.050[\*](#tf1-2){ref-type="table-fn"}    0.019                                           
  C12.DC                Dodecanedioyl-[l]{.smallcaps}-carnitine                                            0.11[\*](#tf1-2){ref-type="table-fn"}         0.047       0.12[\*](#tf1-2){ref-type="table-fn"}     0.028                                           
  C12.1                 Dodecenoyl-[l]{.smallcaps}-carnitine                                               0.065[\*](#tf1-2){ref-type="table-fn"}        0.031       0.008[\*](#tf1-2){ref-type="table-fn"}    0.026                                           
  C14                   Tetradecanoyl-[l]{.smallcaps}-carnitine                                            0.025[\*](#tf1-2){ref-type="table-fn"}        0.0075      0.023[\*](#tf1-2){ref-type="table-fn"}    0.0080                                          
  C14.1                 Tetradecenoyl-[l]{.smallcaps}-carnitine                                            0.016                                         0.0062      0.021                                     0.011                                           
  C14.1.OH              Hydroxytetradecenoyl-[l]{.smallcaps}-carnitine                                     0.015                                         0.0050      0.012[\*](#tf1-2){ref-type="table-fn"}    0.0024                                          
  C14.2                 Tetradecadienyl-[l]{.smallcaps}-carnitine                                          0.006[\*](#tf1-2){ref-type="table-fn"}        0.002       0.006[\*](#tf1-2){ref-type="table-fn"}    0.001                                           
  C14.2.OH              Hydroxytetradecadienyl-[l]{.smallcaps}-carnitine                                   0.01[\*](#tf1-2){ref-type="table-fn"}         0.002       0.01[\*](#tf1-2){ref-type="table-fn"}     0.001                                           
  C16                   Hexadecanoyl-[l]{.smallcaps}-carnitine                                             0.066[†](#tf1-3){ref-type="table-fn"}         0.040       0.043[†](#tf1-3){ref-type="table-fn"}     0.028                                           
  C16.OH                Hydroxyhexadecanoyl-[l]{.smallcaps}-carnitine                                      0.020                                         0.0078      0.021                                     0.0097                                          
  C16.1                 Hexadecenoyl-[l]{.smallcaps}-carnitine                                             0.052[\*](#tf1-2){ref-type="table-fn"}        0.016       0.056[\*](#tf1-2){ref-type="table-fn"}    0.021                                           
  C16.1.OH              Hydroxyhexadecenoyl-[l]{.smallcaps}-carnitine                                      0.021                                         0.011       0.022                                     0.014                                           
  C16.2                 Hexadecadienyl-[l]{.smallcaps}-carnitine                                           0.01                                          0.004       0.01                                      0.004                                           
  C16.2.OH              Hydroxyhexadecadienyl-[l]{.smallcaps}-carnitine                                    0.01[\*](#tf1-2){ref-type="table-fn"}         0.004       0.01[\*](#tf1-2){ref-type="table-fn"}     0.003                                           
  C18                   Octadecanoyl-[l]{.smallcaps}-carnitine                                             0.03[†](#tf1-3){ref-type="table-fn"}          0.0080      0.022[†](#tf1-3){ref-type="table-fn"}     0.012                                           
  C18.1                 Octadecenoyl-[l]{.smallcaps}-carnitine                                             0.20                                          0.14        0.11                                      0.095                                           
  C18.1.OH              Hydroxyoctadecenoyl-[l]{.smallcaps}-carnitine                                      0.042                                         0.022       0.046                                     0.027                                           
  C18.2                 Octadecadienyl-[l]{.smallcaps}-carnitine                                           0.13                                          0.10        0.12                                      0.085                                           
  C2                    Acetyl-[l]{.smallcaps}-carnitine                                                   36.2[‡](#tf1-4){ref-type="table-fn"}          7.27        27.3                                      9.28                                  0.007     
  C3                    Propionyl-[l]{.smallcaps}-carnitine                                                0.428                                         0.117       0.475                                     0.226                                           
  C3.DC, C4.OH          Malonyl-[l]{.smallcaps}-carnitine/hydroxybutyryl-[l]{.smallcaps}-carnitine         0.992                                         0.369       1.45                                      0.538                                 0.01      
  C3.OH                 Hydroxypropionyl-[l]{.smallcaps}-carnitine                                         0.033[\*](#tf1-2){ref-type="table-fn"}        0.0048      0.036[\*](#tf1-2){ref-type="table-fn"}    0.097                                           
  C3.1                  Propenoyl-[l]{.smallcaps}-carnitine                                                0.009[\*](#tf1-2){ref-type="table-fn"}        0.003       0.01[\*](#tf1-2){ref-type="table-fn"}     0.002                                           
  C4                    Butyryl-[l]{.smallcaps}-carnitine                                                  0.188                                         0.0510      0.381                                     0.126                                 \<0.001   
  C4.1                  Butenyl-[l]{.smallcaps}-carnitine                                                  0.030[\*](#tf1-2){ref-type="table-fn"}        0.0078      0.047                                     0.016                                 0.001     
  C5                    Valeryl-[l]{.smallcaps}-carnitine                                                  0.14                                          0.040       0.14                                      0.030                                           
  C5.DC. C6.OH          Glutaryl-[l]{.smallcaps}-carnitine/hydroxyhexanoyl-[l]{.smallcaps}-carnitine       0.10                                          0.032       0.12                                      0.028                                           
  C5.M.DC               Methylglutaryl-[l]{.smallcaps}-carnitine                                           0.015[\*](#tf1-2){ref-type="table-fn"}        0.0029      0.015                                     0.0021                                          
  C5.OH, C3.DC.M        Methylmalonyl-[l]{.smallcaps}-carnitine/hydroxyvaleryl-[l]{.smallcaps}-carnitine   0.559                                         0.101       0.557                                     0.108                                           
  C5.1                  Tiglyl-[l]{.smallcaps}-carnitine                                                   0.059                                         0.012       0.076                                     0.011                                 0.001     
  C5.1.DC               Glutaconyl-[l]{.smallcaps}-carnitine                                               0.013[\*](#tf1-2){ref-type="table-fn"}        0.0021      0.015[\*](#tf1-2){ref-type="table-fn"}    0.0030                                          
  C6, C4.1.DC           Fumaryl-[l]{.smallcaps}-carnitine/hexanoyl-[l]{.smallcaps}-carnitine               0.036[\*](#tf1-2){ref-type="table-fn"}        0.01        0.037[\*](#tf1-2){ref-type="table-fn"}    0.0069                                          
  C6.1                  Hexenoyl-[l]{.smallcaps}-carnitine                                                 0.021[\*](#tf1-2){ref-type="table-fn"}        0.0046      0.030[\*](#tf1-2){ref-type="table-fn"}    0.0077                                0.001     
  C7.DC                 Pimelyl-[l]{.smallcaps}-carnitine                                                  0.044                                         0.018       0.058                                     0.016                                 0.04      
  C8                    Octanoyl-[l]{.smallcaps}-carnitine                                                 0.0916[\*](#tf1-2){ref-type="table-fn"}       0.0101      0.0933[\*](#tf1-2){ref-type="table-fn"}   0.00969                                         
  C8.1                  Octenoyl-[l]{.smallcaps}-carnitine                                                 n.d.                                          n.d.        n.d.                                      n.d.                                            
  C9                    Nonayl-[l]{.smallcaps}-carnitine                                                   0.033[\*](#tf1-2){ref-type="table-fn"}        0.016       0.037[\*](#tf1-2){ref-type="table-fn"}    0.014                                           
  Ala                   Alanine                                                                            769                                           125         793                                       118                                             
  Arg                   Arginine                                                                           101                                           12.1        115                                       20.7                                  0.03      
  Asn                   Asparagine                                                                         56.8                                          25.1        77.8                                      40.2                                            
  Amino acids           Asp                                                                                Aspartate                                     n.d.        n.d.                                      n.d.                                  n.d.      
  Cit                   Citrulline                                                                         40.9                                          12.7        29.0                                      7.42                                  0.005     
  Gln                   Glutamine                                                                          1783[‡](#tf1-4){ref-type="table-fn"}          436.0       1360                                      298.6                                 0.005     
  Glu                   Glutamate                                                                          n.d.                                          n.d.        n.d.                                      n.d.                                  n.d.      
  Gly                   Glycine                                                                            226                                           36.9        499                                       78.5                                  \<0.001   
  His                   Histidine                                                                          76.6                                          13.8        58.2                                      8.81                                  \<0.001   
  Ile                   Isoleucine                                                                         59.1                                          7.79        73.8                                      13.1                                  0.001     
  Leu                   Leucine                                                                            118                                           15.4        138                                       25.7                                  0.01      
  Lys                   Lysine                                                                             162                                           38.9        207                                       59.0                                  0.02      
  Met                   Methionine                                                                         39.4                                          6.29        47.9                                      10.4                                  0.01      
  Orn                   Ornithine                                                                          5.20                                          3.65        9.84                                      4.97                                  0.008     
  Phe                   Phenylalanine                                                                      60.7                                          11.8        68.7                                      12.2                                            
  Pro                   Proline                                                                            76.3                                          12.0        100\.                                     15.6                                  \<0.001   
  Ser                   Serine                                                                             170\.                                         38.1        247                                       51.4                                  \<0.001   
  Thr                   Threonine                                                                          108                                           12.9        153                                       34.8                                  \<0.001   
  Trp                   Tryptophan                                                                         16.9                                          2.77        20.0                                      4.37                                  0.03      
  Tyr                   Tyrosine                                                                           56.1                                          12.9        65.7                                      13.4                                            
  Val                   Valine                                                                             93.5                                          13.0        127                                       23.6                                  \<0.001   
  Sugar                 H1                                                                                 Hexose                                        667         189                                       424                                   202       0.002
  Biogene amines        Creatinine                                                                         Creatinine                                    25.5        4.38                                      23.4                                  3.55      
  ADMA                  Asymetric dimethylarginine                                                         0.854                                         0.268       0.958                                     0.212                                           
  Ac-Orn                Acetylornithine                                                                    2.79                                          0.97        3.53                                      1.03                                            
  Carnosine             Carnosine                                                                          2.95                                          1.20        2.40                                      1.42                                            
  DOPA                                                                                                     0.940                                         0.597       0.725                                     0.352                                           
  Histamine             Histamine                                                                          0.557                                         0.182       1.42                                      0.842                                 0.001     
  Kynurenine            Kynurenine                                                                         0.229                                         0.129       0.303                                     0.151                                           
  PEA                   Phenylethylamine                                                                   n.d.                                          n.d.        n.d.                                      n.d.                                            
  Putrescine            Putrescine                                                                         1.67                                          0.536       1.882                                     0.408                                           
  Serotonin             Serotonin                                                                          0.654                                         0.157       0.323                                     0.081                                 \<0.001   
  Spermidine            Spermidine                                                                         19.8                                          3.76        22.44[‡](#tf1-4){ref-type="table-fn"}     5.19                                            
  Spermine              Spermine                                                                           n.d.                                          n.d.        n.d.                                      n.d.                                            
  α-AAA                 α-Aminoadipic acid                                                                 n.d.                                          n.d.        n.d.                                      n.d.                                            
  Total DMA             Total dimethylarginine                                                             0.434[†](#tf1-3){ref-type="table-fn"}         0.152       0.502[†](#tf1-3){ref-type="table-fn"}     0.102                                           

The quantification range was determined by BIOCRATES and adopted from the manual: "Absolute*IDQ* p150 kit---Analytical Specifications" (BIOCRATES Life Sciences AG, Innsbruck, Austria). Total carnitine was defined as the concentration of all acyl-carnitines measured plus free carnitine. Total acyl-carnitine was defined as the concentration of all measured acyl-carnitines. The acyl/free ratio was defined as the sum of the concentration of all measured acyl-carnitines divided by the concentration of free carniti. n.d. indicates not detected.

Quantification range: ^\*^Mean below LOD (limit of detection)

Mean below LLOQ (lower limit of quantification)

Mean below ULOQ (upper limit of quantification).

![Alterations in metabolite levels. A through D, Concentration of selected metabolites in thioredoxin reductase 2 (*Txnrd2*^−/−^) myocardium obtained from old mice compared with controls. Metabolite class A, amino acids; B, biogenic amines; C, acyl-carnitines; D, hexoses. n=14 for ko and n=15 for ctrl. \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.001. *P*-values are given in the table.](jah30004-e002153-f11){#fig11}

Comparative analysis revealed significantly decreased levels of citrulline, histidine, and glutamine in KO myocardia. The content of all other measured AAs was increased. This change was significant with the exception of alanine, asparagine, phenylalanine, and tyrosine (Figure[1A](#fig01){ref-type="fig"}). Free carnitine (C0) levels in KO hearts significantly exceeded that of control hearts by 24%, while the content of acetyl-carnitine (C2) was 25% lower in KO tissue. Among all measured acyl-carnitines the content of long-chain acyl-carnitine (C14 to C18) species was not altered. Among medium-chain acyl-carnitines (C6 to C12) the content of 2 species was significantly increased (hexenoyl-carnitine \[C6.1\] and pimelyl-carnitine \[C7.1\]), while among short-chain acyl-carnitines (C3 to C5) several were increased (malonyl-carnitine \[C3.DC\], butyryl-carnitine \[C4\], butenyl-carnitine \[C4.1\], and tiglyl-carnitine \[C5.1\]) in KO compared with control tissue (Figure[1C](#fig01){ref-type="fig"}). From the measured biogenic amines, histamine was increased by 153% and serotonin was decreased by 49% in KO tissue (Figure[1B](#fig01){ref-type="fig"}). Finally, the content of hexoses (90% glucose) was 36% lower in KO tissue (Figure[1D](#fig01){ref-type="fig"}).

Quantifying metabolite concentrations provides a "snapshot" of cellular metabolism that does not reflect metabolic flux but has the potential to assign a specific phenotype.[@b39] Thus, the change in metabolite concentration suggests metabolic remodeling in *Txnrd2*^*−/−*^ hearts, and again confirms the existence of cellular stress. In accordance with mitochondrial dysfunction, the altered metabolic signature of *Txnrd2*^*−/−*^ hearts indicates a deregulation of β-oxidation and tricarboxylic acid cycle activity.

Discussion
==========

The present study demonstrates a novel role of *Txnrd2* in the aging heart, including LV function, tissue integrity, and mitochondrial and metabolic alterations. Absence of *Txnrd2* function impairs morphological and functional integrity of mitochondria, as well as being associated with metabolic derangements and contractile dysfunction in the aging mouse heart.

Cardiac-specific ablation of *Txnrd2* was associated with a reduced LV pump function and increased LVESD in KO hearts in middle-aged and old mice. Consistent with systolic dysfunction, fractional shortening and ejection fraction were reduced. The expression of natriuretic peptides, diagnostic markers of cardiovascular disease,[@b40] was increased.

Therefore, TXNRD2 may be critical in the progression of heart failure of patients with ischemic heart disease, genetic cardiomyopathies, or additional disorders. In accordance with this, Sibbing et al identified 3 heterozygous carriers of *Txnrd2* mutations in a cohort of 227 patients diagnosed with dilated cardiomyopathy.[@b41] Further, adequate selenium supply and functional selenoproteins are factors in preventing chronic heart disease.[@b11],[@b42] To date, clinical trials do not support use of selenium supplements for the prevention of chronic heart disease in healthy adults.[@b43] However, the genetic impact of single selenoproteins is not well studied and this, along with the individuals' basic selenium intake, may have implications on selenium supplementation.

Mitochondrial degeneration observed in cardiomyocytes of aged KO mice could be a direct consequence of *Txnrd2* ablation leading to decreased energy supply, which, in turn, reduces myocardial contractility. Indeed, *Txn2* haploinsufficiency has been associated with decreased ATP production in vitro, particularly in tissues with high energy demand, such as heart.[@b44] Interestingly, despite obvious mitochondrial degeneration in ultrastructure, overall mitochondrial content was reduced only in old KO mice, indicating that compensatory mechanisms exist but become increasingly ineffective during aging. Consistently, *Tfam*, a gene involved in mitochondrial biogenesis, was lower in old but not in middle-aged mice.

Moreover, autophagy, a cellular process responsible for turnover of organelles and cytoplasmic proteins, is the major mitochondrial degradation pathway.[@b45] Autophagy is typically accompanied by accumulation of undegradable organic and anorganic material in secondary lysosomes, called lipofuscin. This age pigment was more pronounced in *Txnrd2*^−/−^ hearts. Western blotting revealed an increase in the 18-kDa LC3-I signal in the myocardium of old KOs, while the LC3-II signal, representing the 16-kDa active isoform localized to autophagosome membranes and degraded during autophagy,[@b46] was not consistently increased. Autolysosomes are LAMP1 and LC3 positive.[@b47] The increase in LAMP1-positive vesicles is indicative of increased autophagic flux rather than downstream inhibition, as suppression of autophagy in upstream or downstream steps is believed to be accompanied by a decrease in autolysosomes.[@b48] p62 protein accumulates in authopagy-deficient cells; however, p62 can also be transcriptionally regulated during autophagy. Moreover, p62 is thought to be upregulated in response to oxidative stress.[@b49] As both p62 protein and *p62* mRNA were upregulated, this could be due to the active stress response in *Txnrd2*^*−/−*^ hearts.

The slight but robustly increased ROS generation in isolated KO mitochondria seems to be compensated in vivo by a cytoprotective response, as suggested by heightened HSP25, HSP60, catalase, and GSH. Furthermore, *Txnrd2*^−/−^ hearts did not accumulate peroxidized lipids on the whole cell or mitochondrial level, as assessed with anti--4-hydroxy-2-nonenal immunoblots (data not shown). There was also no evidence for increased oxidative damage to DNA and RNA as assessed with anti--8-hydroxy-2′-deoxyguanosine/8-hydroxyguanosin immunohistochemistry (data not shown). This suggests that, despite *Txnrd2* deficiency, a balance exists between mitochondrial ROS production and detoxification. Despite increased GSH levels in *Txnrd2*^−/−^ hearts, the GSH/GSSG ratio was not altered, indicating that the redox balance is not disrupted.

Isolated mitochondria from aging KO mice, although lacking signs of uncoupled respiration, used significantly less oxygen, pointing toward a reduced oxidative phosphorylation. Intriguingly, the ATP content in the whole myocardium did not differ, again supporting the concept of an active compensation. Decreased O~2~ consumption may be a consequence of an adaptive response resulting in reduced heart contractility, as energy supply is limited.

Mitochondria are oxygen sensors that increase ROS generation under hypoxic conditions and regulate a variety of responses, including HIF1α activation. The HIF1α stabilization in our model could not be attributed to mRNA changes. This posttranslational regulation is in agreement with the majority of findings.[@b50],[@b51] Moreover, overexpression of TRX2 in hypoxic HEK cells reduced HIF1α accumulation, and this was attributed to *Trx2* influencing HIF1α protein synthesis.[@b35]

Long-term HIF1α stabilization in mouse heart was associated with cardiomyopathy and a metabolic shift toward higher glucose utilization during aging. Aging *Hif1-*α^*tg*^ mice, overexpressing HIF1α protein, spontaneously developed thicker septum walls and decreased fractional shortening.[@b52] Likewise, constitutively active HIF1α in adult mouse myocardium resulted in cardiomyopathy, characterized by higher heart weight and lower fractional shortening.[@b53]

*Glut1* was the only HIF1α target gene upregulated in our model. In old *Txnrd2*^*−/−*^ mice, the cardiac expression of enzymes providing reduction equivalents to the electron transport chain was changed. Genes involved in lipid metabolism, like *Pgc1a* and *Ppara*, were reduced. Mitochondrial uncoupling proteins 2 and 3 have been suggested not as physiological uncouplers but rather as influencing cellular metabolism and ROS production.[@b54],[@b55] They were regulated toward reduced ROS production. The translational signature in *Txnrd2*^*−/−*^ hearts supports the hypothesis of an altered metabolic homeostasis attributed to changes in HIF1α stabilization. However, a decreased mRNA content of nuclear-encoded mitochondrial genes could be contributing to this signature.

Acyl-carnitines are used as biomarkers for mitochondrial function because they are byproducts of fatty acid, glucose, and AA oxidation and their accumulation indicates deregulated β-oxidation and mitochondrial dysfunction.[@b56],[@b57] In *Txnrd2*^*−/−*^ and control hearts, the 2 major carnitines were free carnitine (≈80% and ≈72%) and acetyl-carnitine (≈17% and ≈25%, respectively).

Among acyl-carnitines, short-chain acyl-carnitines were the main species in KO and control hearts (≈73% and ≈67%), while medium- and long-chain acyl-carnities accounted for the rest of the acyl-carnitine pool at relatively equal amounts. The increased content of some short-chain (C3-DC, C4.1, C5.1) and medium-chain (C6.1, C7-DC) acyl-carnitine species further supports the concept of a deregulated flux through oxidative pathways in *Txnrd2*^−/−^ myocardium.

The significant increase of nearly every AA in *Txnrd2*^*−/−*^ hearts compared with controls suggests either that more AAs are supplied by protein catabolism, that there is a decreased protein biosynthesis, or that there is a decreased influx of AAs into the citric acid cycle. Both essential and nonessential AAs are increased, indicating protein catabolism origin. Glutamine, the most abundant AA in control and KO tissue, was significantly decreased in *Txnrd2*^*−/−*^ hearts. Among several functions, glutamine can serve as energy source by feeding carbons via α-ketoglutarate into the tricarboxylic acid cycle. Additionally, it serves as a precursor for glutathione and could act as a remedy against redox imbalance. The significant hexose reduction in old KO hearts also points toward an increased glucose utilization.

This study identifies a critical role for *Txnrd2* in preserving the morphological and functional integrity of mitochondria in aging cardiomyocytes. Different experimental approaches clearly demonstrated cellular stress in aged KO hearts. Thus, TXNRD2 not only is important in balancing acute stress like ischemia--reperfusion but also is essential in avoiding age-related functional cardiac decline.
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